SecBot SecBot
8-K ·Filed Jun 11, 2026

VSEE

VSEE HEALTH, INC.
BEARISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001185185-26-002467
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The SEPA creates persistent downward pressure as the company can repeatedly sell shares at a discount. Monitor for the first Advance Notice and the effectiveness of the resale registration statement—once effective, the investor can immediately sell into the market, likely capping any rally. The combination of a halved revenue base and this equity line suggests the company is burning cash and has limited organic funding alternatives. Short sellers should watch for volume spikes following registration statement effectiveness.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
VSEE ▼ -64.65% at T+60d
SHORT call ✓ call won +64.65% · α vs SPY +67.91% · entry $0.1420 → $0.0502
Entry = T+0 close
Jun 11, 2026
via day close
T+1d
-13.59%
call +13.59% · α +15.35%
$0.1227
settled 5mo ago
T+5d
-18.59%
call +18.59% · α +19.26%
$0.1156
settled 4mo ago
T+20d
-21.83%
call +21.83% · α +23.61%
$0.1110
settled 4mo ago
T+60d
-64.65%
call +64.65% · α +67.91%
$0.0502
settled 7w ago

Price Chart

Loading chart...

Executive Summary

VSee Health entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. for up to $10M in common stock sales at a 3% discount to the lowest VWAP, issued 532,481 commitment shares upfront, and committed to file a resale registration statement. This comes just 6 days after spinning off its VSee Lab subsidiary (which contributed ~50% of FY2025 revenue) and deleveraging the balance sheet via a management-led transaction. The SEPA effectively replaces the lost revenue-generating capacity with a highly dilutive equity line, potentially flooding the market with shares up to ~20% of the current float at heavy discount.

Key Financial Metrics

Deal Value
$10.0M
Offering Size
$10.0M
Dilution
19.99%

Key Facts

  • SEPA allows VSee to require YA II PN to purchase up to $10M of common stock at 97% of the lowest daily VWAP over a 3-day pricing period
  • Company issued 532,481 Commitment Shares (1% of $10M Commitment Amount / pre-deal VWAP) as a fully earned fee
  • Exchange Cap set at 9,715,140 shares (19.99% of pre-deal outstanding), with no stockholder approval threshold met unless average price exceeds $0.1878/share
  • SEPA runs until June 2, 2029, and the company may terminate on 5 trading days' notice
  • Transaction was completed just 6 days after VSee spun off VSee Lab to former co-CEO Milton Chen, shrinking revenue by ~50% (from $14.6M to ~$7.3M in FY2025)
  • Current market cap is ~$8M; the $10M commitment amount is 125% of market cap, implying maximum potential dilution of over 100% of current shares if fully drawn at current prices

Financial Impact

Potential dilution up to 20% of shares outstanding (Exchange Cap) without stockholder approval, and the $10M commitment exceeds the company's current $8M market cap, creating severe dilution risk. The 3% discount to VWAP plus the up-front commitment shares (532,481) impose an immediate cost of capital of ~5-10% on any draws.

dilutionshare countcash balancemarket capitalization

Risk Factors

  • Immediate dilution of up to 19.99% of shares outstanding without stockholder approval
  • Potential for substantially more dilution if stockholder approval is obtained or the average price threshold ($0.1878) is exceeded
  • The Yorkville-type SEPA structure is known to create 'death spiral' dynamics where increased selling depresses the stock, triggering more shares to be issued at lower prices
  • Revenue base just halved (~$7.3M to ~$7.3M post-spin), making the company even more dependent on equity financing to sustain operations
  • Nasdaq continued listing may be at risk if the stock price declines further from current $0.16 level (near potential compliance thresholds)

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001185185-26-002467
Document: vsee8k061026.htm0001185185-26-002467
Document: 0001185185-26-002467-index-headers.html0001185185-26-002467
Document: 0001185185-26-002467-index.html0001185185-26-002467
Document: 0001185185-26-002467.txt0001185185-26-002467
3 reports for VSEE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VSEE — sortable, filterable
TypeNow
Oct 1, 2026
25d ago
S-1
BEARISH ★ 6/10
$0.0193awaiting T+60——
Jun 26, 2026
17w ago
8-K
BEARISH ★ 6/10
$0.1109 $0.0502▲ +54.73%▲ +59.12%—
Jun 11, 2026
19w ago
8-K
BEARISH ★ 7/10
$0.1420 $0.0502▲ +64.65%▲ +67.91%—
Showing 3 of 3

US Market Status

Market Closed — Opens Tue (15h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026